**Supplementary Table 1. Primary and Secondary Outcomes at 14 Days or Hospital Discharge According to the Quartiles of Baseline NIHSS Scores**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Outcome variables | NIHSS 0-2 | | | | NIHSS 3-4 | | | | NIHSS 5-8 | | | | NIHSS ≥9 | | | | P  value for homogeneity |
| Treatment  (n=536) | Control  (n=498) | OR  (95% CI) | P value | Treatment  (n=529) | Control  (n=511) | OR  (95% CI) | P value | Treatment  (n=562) | Control  (n=599) | OR  (95% CI) | P value | Treatment  (n=404) | Control  (n=417) | OR  (95% CI) | P value |
| **Primary outcome** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Death or major disability\*, No. (%) | 35 (6.5) | 25 (5.0) | 1.32  (0.78, 2.24) | 0.30 | 99 (18.7) | 88 (17.2) | 1.11  (0.81, 1.52) | 0.53 | 220 (39.2) | 230 (38.4) | 1.03  (0.82, 1.31) | 0.79 | 329 (81.4) | 338 (81.1) | 1.03  (0.72, 1.46) | 0.89 | 0.85 |
| **Secondary outcomes** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Score on modified Rankin scale†, median (IQR) | 1.0  (0.0, 1.0) | 1.0  (1.0, 1.0) |  | 0.40 | 1.0  (1.0, 2.0) | 1.0  (1.0, 2.0) |  | 0.46 | 2.0  (2.0, 3.0) | 2.0  (2.0, 3.0) |  | 0.90 | 4.0  (3.0, 5.0) | 4.0  (3.0, 4.0) |  | 0.32 | 0.57 |
| Participants, No. (%) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 0 (no symptoms) | 137 (25.6) | 104 (20.9) | 1.11  (0.87, 1.40)‡ | 0.40 | 35 (6.6) | 28 (5.5) | 0.97  (0.19, 4.81)‡ | 0.97 | 35 (0.0) | 28 (5.5) | 0.92  (0.73, 1.15)‡ | 0.45 | 8 (2.0) | 4 (1.0) | 0.88  (0.69, 1.13)‡ | 0.78 | 0.57 |
| 1 (no significant disability despite symptoms) | 295 (55.0) | 303 (60.8) |  |  | 232 (43.9) | 247 (48.3) |  |  | 232 (2.1) | 247 (48.3) |  |  | 11 (2.7) | 23 (5.5) |  |  |  |
| 2 (slight disability) | 69 (12.9) | 66 (13.3) |  |  | 163 (30.8) | 148 (29.0) |  |  | 163 (4.2) | 148 (29.0) |  |  | 56 (13.9) | 52 (12.5) |  |  |  |
| 3 (moderate disability) | 13 (2.4) | 11 (2.2) |  |  | 68 (12.9) | 55 (10.8) |  |  | 68 (6.3) | 55 (10.8) |  |  | 82 (20.3) | 93 (22.3) |  |  |  |
| 4 (moderately severe disability) | 16 (3.0) | 11 (2.2) |  |  | 25 (4.7) | 30 (5.9) |  |  | 25 (30.5) | 30 (5.9) |  |  | 145 (35.9) | 157 (37.7) |  |  |  |
| 5 (severe disability) | 4 (0.8) | 3 (0.6) |  |  | 3 (0.6) | 0 (0.0) |  |  | 3 (41.1) | 0 (0.0) |  |  | 86 (21.3) | 68 (16.3) |  |  |  |
| 6 (dead) | 2 (0.4) | 0 (0.0) |  |  | 3 (0.6) | 3 (0.6) |  |  | 3 (15.8) | 3 (0.6) |  |  | 16 (4.0) | 20 (4.8) |  |  |  |
| Death, No. (%) | 2 (0.4) | 0 (0.0) | … | … | 3 (0.6) | 3 (0.6) | 0.97  (0.19, 4.81) | 0.97 | 4 (0.7) | 2 (0.3) | 2.14  (0.39, 11.73) | 0.38 | 16 (4.0) | 20 (4.8) | 0.82  (0.42, 1.60) | 0.56 | 0.79 |
| Duration of initial hospitalization, median (IQR), day | 12.0  (9.0, 14.0) | 12.0  (8.0, 14.0) |  | 0.13 | 12.0  (9.0, 14.0) | 12.0  (9.0, 14.0) |  | 0.61 | 13.0  (9.0, 14.0) | 13.0  (9.0, 14.0) |  | 0.58 | 13.0  (9.0, 15.0) | 13.0  (9.0, 15.0) |  | 0.30 | 0.50 |

Abbreviations: CI=confidence interval; IQR=interquartile range; OR=odds ratio.

\* Modified Rankin Score of 3 or greater. † Scores on the modified Rankin Scale, for which a score of 0 indicates no symptoms, a score of 5 indicates severe disability, and a score of 6 indicates death. ‡ Odds of a 1-unit higher modified Rankin score.

**Supplementary Table 2. Secondary Outcomes at 3-Month Post-treatment Follow-up Visit According to the Quartiles of Baseline NIHSS Scores**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | NIHSS 0-2 | | | | NIHSS 3-4 | | | | NIHSS 5-8 | | | | | NIHSS ≥9 | | | | P value for homogeneity |
| Treatment  (n=1050) | Control  (n=993) | BP difference or  OR (95% CI) | P value | Treatment  (n=848) | Control  (n=901) | BP difference or  OR (95% CI) | P value | | Treatment  (n=549) | Control  (n=583) | BP difference or  OR (95% CI) | P value | Treatment  (n=61) | Control  (n=70) | BP difference or  OR (95% CI) | P value |
| BP at 3 months after randomization, mean (SD) mm Hg | | | | |  |  |  |  | |  |  |  |  |  |  |  |  |  |
| Systolic | 137.9 (10.1) | 141.5 (12.9) | -3.5  (-5.0, -2.1) | <0.001 | 139.1 (11.8) | 142.5 (12.3) | -3.4  (-4.9, -1.9) | <0.001 | | 139.4 (12.3) | 141.8 (11.1) | -2.4  (-3.8, -1.0) | <0.001 | 141.5 (12.4) | 143.4 (14.1) | -2.0  (-3.9, -0.0) | 0.05 | 0.45 |
| Diastolic | 85.3 (6.8) | 86.8 (7.6) | -1.5  (-2.4, -0.6) | <0.001 | 85.7 (8.2) | 87.6 (8.2) | -1.9  (-2.9, -0.9) | <0.001 | | 86.4 (8.6) | 87.5 (7.9) | -1.1  (-2.1, -0.1) | 0.03 | 86.7 (7.8) | 87.8 (8.4) | -1.1  (-2.2, 0.1) | 0.08 | 0.62 |
| Use of antihypertensive medication, No. (%) | 441 (84.0) | 378 (75.1) | 1.74  (1.28, 2.37) | <0.001 | 441 (84.0) | 389 (77.3) | 1.54  (1.13, 2.10) | 0.007 | | 470 (85.6) | 435 (74.6) | 2.0  (1.50, 2.7) | <0.001 | 315 (81.0) | 294 (71.7) | 1.68  (1.21, 2.34) | 0.002 | 0.66 |
| Death or major disability, No. (%)\* | 29 (5.5) | 22 (4.5) | 1.24  (0.71, 2.20) | 0.45 | 60 (11.4) | 78 (15.5) | 0.70  (0.49, 1.01) | 0.06 | | 152 (27.7) | 140 (24.0) | 1.21  (0.93, 1.58) | 0.16 | 259 (66.6) | 262 (63.9) | 1.13  (0.84, 1.51) | 0.09 | 0.43 |
| Score on modified Rankin scale†, median (IQR) | 1.0  (0.0, 1.0) | 1.0  (0.0, 1.0) |  | 0.62 | 1.0  (1.0, 2.0) | 1.0  (1.0, 2.0) |  | 0.37 | | 2.0  (1.0, 3.0) | 2.0  (1.0, 2.0) |  | 0.67 | 3.0  (2.0, 4.0) | 3.0  (2.0, 4.0) |  | 0.48 | 0.66 |
| Participants, No. (%) |  |  |  |  |  |  |  |  | |  |  |  |  |  |  |  |  |  |
| 0 (no symptoms) | 210 (40.0) | 192 (39.2) | 0.94  (0.75, 1.19)‡ | 0.62 | 95 (18.1) | 86 (17.1) | 1.11  (0.89, 1.39)‡ | 0.37 | | 59 (10.8) | 50 (8.6) | 0.96  (0.77, 1.18)‡ | 0.66 | 13 (3.3) | 13 (3.2) | 0.92  (0.72, 1.17)‡ | 0.48 | 0.66 |
| 1 (no significant disability despite symptoms) | 222 (42.3) | 230 (46.9) |  |  | 235 (44.8) | 223 (44.3) |  |  | | 167 (30.4) | 192 (32.9) |  |  | 42 (10.8) | 44 (10.7) |  |  |  |
| 2 (slight disability) | 64 (12.2) | 46 (9.4) |  |  | 135 (25.7) | 116 (23.1) |  |  | | 171 (31.2) | 201 (34.5) |  |  | 75 (19.3) | 91 (22.2) |  |  |  |
| 3 (moderate disability) | 14 (2.7) | 16 (3.3) |  |  | 38 (7.2) | 52 (10.3) |  |  | | 94 (17.1) | 86 (14.8) |  |  | 107 (27.5) | 111 (27.1) |  |  |  |
| 4 (moderately severe disability) | 10 (1.9) | 4 (0.8) |  |  | 9 (1.7) | 14 (2.8) |  |  | | 38 (6.9) | 34 (5.8) |  |  | 79 (20.3) | 78 (19.0) |  |  |  |
| 5 (severe disability) | 2 (0.4) | 2 (0.4) |  |  | 0 (0.0) | 4 (2.8) |  |  | | 9 (1.6) | 10 (1.7) |  |  | 32 (8.2) | 37 (9.0) |  |  |  |
| 6 (dead) | 3 (0.6) | 0 (0.0) |  |  | 13 (2.5) | 8 (1.6) |  |  | | 11 (2.0) | 10 (1.7) |  |  | 41 (10.5) | 36 (8.8) |  |  |  |
| Death, No. (%) | 3 (0.6) | 0 (0.0) | … | … | 13 (2.5) | 8 (1.6) | 1.57  (0.65, 3.82) | 0.32 | | 11 (2.0) | 10 (1.7) | 1.17  (0.49, 2.78) | 0.72 | 41 (10.5) | 36 (8.8) | 1.22  (0.76, 1.96) | 0.40 | 0.96 |
| Recurrent Stroke, No. (%) | 7 (1.3) | 7 (1.4) | 0.93  (0.33, 2.68) | 0.90 | 9 (1.7) | 13 (2.6) | 0.66  (0.28, 1.55) | 0.47 | | 6 (1.1) | 17 (2.9) | 0.37  (0.15, 0.94) | 0.04 | 6 (1.6) | 6 (1.5) | 1.05  (0.33, 3.27) | 0.94 | 0.47 |
| Vascular events, No. (%)†† | 8 (1.5) | 7 (1.4) | 1.07  (0.39, 2.97) | 0.90 | 14 (2.7) | 16 (3.2) | 0.83  (0.40, 1.73) | 0.62 | | 9 (1.7) | 20 (3.4) | 0.47  (0.21, 1.04) | 0.06 | 17 (4.5) | 16 (4.0) | 1.12  (0.56, 2.24) | 0.76 | 0.41 |
| Death or vascular events, No. (%) | 10 (1.9) | 7 (1.4) | 1.34  (0.51, 3.5) | 0.86 | 21 (4.0) | 21 (4.2) | 0.96  (0.52, 1.77) | 0.89 | | 17 (3.1) | 25 (4.3) | 0.71  (0.38, 1.34) | 0.29 | 44 (11.3) | 41 (10.0) | 1.15  (0.73, 1.80) | 0.22 | 0.60 |

Abbreviations: BP=blood pressure; CI=confidence interval; IQR=interquartile range; OR=odds ratio.

\* Modified Rankin Score of 3 or greater. † Scores on the modified Rankin Scale, for which a score of 0 indicates no symptoms, a score of 5 indicates severe disability, and a score of 6 indicates death. ‡ Odds of a 1-unit higher modified Rankin score. †† Includes vascular deaths, nonfatal stroke, nonfatal myocardial infarction, hospitalized and treated angina, hospitalized and treated congestive heart failure, and hospitalized and treated peripheral arterial disease.